Search Results - "Justin, Saira"

  • Showing 1 - 9 results of 9
Refine Results
  1. 1

    Chronic Sulforaphane Administration Inhibits Resistance to the mTOR-Inhibitor Everolimus in Bladder Cancer Cells by Justin, Saira, Rutz, Jochen, Maxeiner, Sebastian, Chun, Felix K-H, Juengel, Eva, Blaheta, Roman A

    “…Progressive bladder cancer growth is associated with abnormal activation of the mammalian target of the rapamycin (mTOR) pathway, but treatment with an mTOR…”
    Get full text
    Journal Article
  2. 2

    Bladder Cancer Metastasis Induced by Chronic Everolimus Application Can Be Counteracted by Sulforaphane In Vitro by Justin, Saira, Rutz, Jochen, Maxeiner, Sebastian, Chun, Felix K-H, Juengel, Eva, Blaheta, Roman A

    “…Chronic treatment with the mTOR inhibitor, everolimus, fails long-term in preventing tumor growth and dissemination in cancer patients. Thus, patients…”
    Get full text
    Journal Article
  3. 3

    Investigating pathogenic SNP of PKCι in HCV-induced hepatocellular carcinoma by Khan, Naila, Khan, Khushbukhat, Badshah, Yasmin, Trembley, Janeen H., Ashraf, Naeem Mahmood, Shabbir, Maria, Danish, Lubna, Afsar, Tayyaba, Almajwal, Ali, Justin, Saira, Hasan, Zafarul, Razak, Suhail

    Published in Scientific reports (02-08-2023)
    “…Hepatocellular carcinoma is a leading cause of cancer-related deaths due to its complexity in diagnosis, chemo-resistance, and aggressive nature. Identifying…”
    Get full text
    Journal Article
  4. 4

    Detection of human papillomavirus in archival bladder and ovarian cancer samples by Fatima, Bukhtawar, Masud, Rabia, Sultana, Nuzhat, Javed, Aneela, Justin, Saira

    Published in Clinical epidemiology and global health (01-07-2023)
    “…Human papillomavirus (HPV) is a well-established causative agent of cervical cancer. However, its role in the development of bladder and ovarian cancer is…”
    Get full text
    Journal Article
  5. 5

    Sulforaphane as an adjunctive to everolimus counteracts everolimus resistance in renal cancer cell lines by Juengel, Eva, Euler, Stephanie, Maxeiner, Sebastian, Rutz, Jochen, Justin, Saira, Roos, Frederik, Khoder, Wael, Nelson, Karen, Bechstein, Wolf O., Blaheta, Roman A.

    Published in Phytomedicine (Stuttgart) (15-04-2017)
    “…The mechanistic target of rapamycin (mTOR) inhibitors, everolimus and temsirolimus, have widened therapeutic options to treat renal cell carcinoma (RCC)…”
    Get full text
    Journal Article
  6. 6

    Low Dosed Curcumin Combined with Visible Light Exposure Inhibits Renal Cell Carcinoma Metastatic Behavior In Vitro by Rutz, Jochen, Maxeiner, Sebastian, Justin, Saira, Bachmeier, Beatrice, Bernd, August, Kippenberger, Stefan, Zöller, Nadja, Chun, Felix K-H, Blaheta, Roman A

    Published in Cancers (28-01-2020)
    “…Recent documentation shows that a curcumin-induced growth arrest of renal cell carcinoma (RCC) cells can be amplified by visible light. This study was designed…”
    Get full text
    Journal Article
  7. 7

    Low Dosed Curcumin Combined with Visible Light Exposure Inhibits Renal Cell Carcinoma Metastatic Behavior in Vitros by Rutz, Jochen, Maxeiner, Sebastian, Justin, Saira, Bachmeier, Beatrice, Bernd, August, Kippenberger, Stefan, Zöller, Nadja, Chun, Felix K.-H., Blaheta, Roman A.

    Published in Cancers (28-01-2020)
    “…Recent documentation shows that a curcumin-induced growth arrest of renal cell carcinoma (RCC) cells can be amplified by visible light. This study was designed…”
    Get full text
    Journal Article
  8. 8

    Chronic Sulforaphane Application Does Not Induce Resistance in Renal Cell Carcinoma Cells by Rutz, Jochen, Juengel, Eva, Euler, Stephanie, Maxeiner, Sebastian, Justin, Saira, Roos, Frederik, Chun, Felix K-H, Blaheta, Roman A

    Published in Anticancer research (01-11-2018)
    “…Since the natural compound sulforaphane (SFN) has been shown to stop tumor growth, renal cell carcinoma (RCC) patients often use this drug in addition to their…”
    Get full text
    Journal Article
  9. 9

    Sulforaphane inhibits proliferation and invasive activity of everolimus-resistant kidney cancer cells in vitro by Juengel, Eva, Maxeiner, Sebastian, Rutz, Jochen, Justin, Saira, Roos, Frederik, Khoder, Wael, Tsaur, Igor, Nelson, Karen, Bechstein, Wolf O, Haferkamp, Axel, Blaheta, Roman A

    Published in Oncotarget (20-12-2016)
    “…Although the mechanistic target of rapamycin (mTOR) inhibitor, everolimus, has improved the outcome of patients with renal cell carcinoma (RCC), improvement is…”
    Get full text
    Journal Article